Hydroxyurea (HU) cytoreduction is usually administered to patients with chronic myeloid leukemia before starting any tyrosine kinase inhibitors (TKIs) therapy. However, up to date, there is no evidence of any benefit of hydroxyurea pre-treatment. Conversely, evidence has been provided on both the prognostic significance of the quantitative assessment of expression at diagnosis and the individual decline of the slope.
View Article and Find Full Text PDFBackground: Acquired haemophilia A (AHA) is a rare and severe bleeding disorder generally associated with pregnancy or aging. Spontaneous remission and prompt inhibitor eradication are described more frequently in postpartum cases. We evaluated retrospectively 15 postpartum AHA cases between 2007 and 2023 in order to evaluate response in terms of inhibitor eradication.
View Article and Find Full Text PDFHaematologica
March 2025
Not available.
View Article and Find Full Text PDFThe GIMEMA LAL2317 protocol investigated the frontline chemotherapy-blinatumomab combination in adult Philadelphia- CD19+ B-lineage acute lymphoblastic leukemia (Ph- B-ALL) to improve minimal residual disease (MRD) response and clinical outcome. Two cycles of intravenous blinatumomab were administered after chemotherapy cycles 3 and 6. The primary endpoint was the rate of molecular MRD negativity following blinatumomab 1.
View Article and Find Full Text PDFL., an invasive plant from South Africa, has developed into a severe ecological threat in many Mediterranean and temperate areas by replacing native flora and modifying ecosystems. Although this species has detrimental effects on the ecosystem, it has unrealized potential as a significant bioresource.
View Article and Find Full Text PDF